Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia

다국어 초록 (Multilingual Abstract)

Background/Aims: This multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome.
Methods: In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels ≥ 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for over 6 weeks.
Results: After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups. The safety and tolerability of the two agents were similar.
Conclusions: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals. (Korean J Intern Med 2010;25:27-35)

참고문헌 (Reference)

1 Boden WE, "Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management" 18 : 278-285, 2003

2 최성희, "The Prevalence of the Metabolic Syndrome in Korean Adults: Comparison of WHO and NCEP Criteria" 연세대학교의과대학 46 (46): 198-205, 2005

3 Yood MU, "Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy" 152 : 777-784, 2006

4 Hyuk Sang Kwon, "Prevalence and Clinical Characteristics of the Metabolic Syndrome in Middle-Aged Korean Adults; Chungju Insulin Resistance Cohort Study (CIRC Study)" 대한내과학회 20 (20): 310-316, 2005

5 Brewer HB Jr, "New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines" 26 : III19-III24, 2003

6 Dekker JM, "Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study" 112 : 666-673, 2005

7 Young-Kwon Kim, "Impact of the Metabolic Syndrome and Its Components on Pulse Wave Velocity" 대한내과학회 21 (21): 109-115, 2006

8 National Cholesterol Education Program (NCEP), "Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)" 285 : 2486-2497, 2001

9 Leibovitz E, "Efficacy of atorvastatin in treating high risk patients to reach low density lipoproteincholesterol goals: the Treat to Target (TTT-Israel) Study" 4 : 407-410, 2002

10 Deedwania PC, "Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome" 95 : 360-366, 2005

11 Naples M, "Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization" 198 : 94-103, 2008

12 Davidson MH, "Differences between clinical trial efficacy and realworld effectiveness" 12 : S405-S411, 2006

13 McKenney JM, "Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial" 19 : 689-698, 2003

14 Clearfield MB, "Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)" 7 (7): 2006

15 Deedwania PC, "Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)" 99 : 1538-1543, 2007

16 Ferdinand KC, "Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial" 97 : 229-235, 2006

17 Grundy SM, "Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management" 109 : 551-556, 2004

18 Pivatto I, "Association between proinsulin, insulin, proinsulin/insulin ratio, and insulin resistance status with the metabolic syndrome" 51 : 1128-1133, 2007

19 Stalenhoef AF, "A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study" 26 : 2664-2672, 2005